Total revenues
Breakdown
Segments
Tyvaso DPIView metric
Nebulized TyvasoView metric
RemodulinView metric
OrenitramView metric
UnituxinView metric
AdcircaView metric
OtherView metric
Total TyvasoView metric
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Tyvaso DPI | $258.3M | $274.6M | $273.2M | $302.5M | $315.2M | $336.2M | $338.6M | $330.3M |
| Orenitram | $107.1M | $113.2M | $107.8M | $120.7M | $123.9M | $131.1M | $121.2M | $135.6M |
| Nebulized Tyvaso | $139.9M | $159.2M | $142.7M | $163.8M | $154.4M | $141.8M | $125.7M | $127.2M |
| Remodulin | $147.3M | $128.3M | $134.5M | $138.2M | $134.7M | $125.9M | $128M | $126.6M |
| Unituxin | $51.7M | $61.1M | $67.5M | $58.2M | $58.4M | $47.9M | $62.3M | $53.6M |
| Adcirca | $5.7M | $7M | $4.7M | $6M | $6.5M | $9.7M | $7.8M | $2.9M |
| Total | $714.9M | $748.9M | $735.9M | $794.4M | $798.6M | $799.5M | $790.2M | $781.5M |